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We studied the metabolism of 14,15-dehydro-leukotriene A
%
(14,15-dehydro-LTA
%
) by human platelet leukotriene C
%
(LTC
%
)
synthase and polymorphonuclear leucocyte (PMNL) leukotriene
A
%
(LTA
%
) hydrolase. Metabolites were separated and identified
using reversed-phase HPLC coupled to diode-array UV de-
tection. Human platelets metabolize 14,15-dehydro-LTA
%
to
14,15-dehydro-LTC
%
with apparent kinetics identical with auth-
entic LTA
%
. Metabolism to 14,15-dehydro-LTC
%
is inhibited by
MK-886, a reported LTC
%
synthase inhibitor in human platelets,
with a potency comparable with that shown by LTA
%
. In contrast,
neither human red-blood-cell lysates nor human PMNL enzym-
INTRODUCTION
Leukotrienes (LTs), namely leukotriene B
%
(LTB
%
) and cysteinyl
leukotrienes leukotriene C
%
(LTC
%
), leukotriene D
%
and leuko-
triene E
%
, represent a family of potent, biologically active
compounds. They are synthesized from the unstable epoxy
intermediate leukotriene A
%
(LTA
%
) through the action of two
enzymes: LTA
%
hydrolase, which catalyses the formation of
LTB
%
, and LTC
%
synthase, which conjugates glutathione and
LTA
%
, giving rise to LTC
%
[1]. Synthesis of LTB
%
and LTC
%
can
be carried out either within the same cell, which also contains the
enzyme 5-lipoxygenase, catalysing the conversion of arachidonic
acid into LTA
%
, or in different cells. This phenomenon, whereby
a cell is able to transfer the unstable intermediate LTA
%
to a
different cell, which carries out the final conversion into LTB
%
or
LTC
%
, has been termed ‘transcellular biosynthetic pathway of
leukotrienes ’. A number of examples supporting the importance
of this pathway for LT biosynthesis have been reported over the
last decade [2–4].
LTA
%
hydrolase and LTC
%
synthase may represent potential
independent targets for drug activity, and both enzymes have
been cloned and sequenced [5–7]. Studies on the mechanism-
based inactivation of the LTA
%
hydrolase by LTA
%
led to the
identification of a potential site for irreversible binding of LTA
%
on LTA
%
hydrolase [8].
Several analogues of LTA
%
have been used by different groups
to test the influence of structural modifications on the enzymic
activity of LTA
%
hydrolase or LTC
%
synthase [9–12]. We report
on a novel LTA
%
analogue, tested both on human platelet LTC
%
synthase and on human erythrocyte and polymorphonuclear
leucocyte (PMNL) LTA
%
hydrolase.
MATERIALS AND METHODS
Human blood (40 ml) was withdrawn from healthy donors that
had not taken medications for at least 1 week; it was collected
into a 50 ml polypropylene centrifuge tube containing 5.7 ml of
Abbreviations used: PMNL, polymorphonuclear leukocytes ; LT, leukotriene ; LTA4, leukotriene A4 ; LTB4, leukotriene B4 ; LTC4, leukotriene C4 ; RT,
room temperature ; PBS= , PBS without Ca2+ and Mg2+ ; RP-HPLC, reversed-phase HPLC.
1 To whom correspondence should be addressed.
ically convert 14,15-dehydro-LTA
%
into 14,15-dehydro-leuko-
triene B
%
. Minor amounts of 14,15-dehydro-LTC
%
, observed in
some PMNL preparations, result from variable eosinophil con-
tamination, as confirmed using highly purified neutrophil and
eosinophil-enriched preparations. In addition, 14,15-dehydro-
LTA
%
irreversibly inhibits PMNL LTA
%
hydrolase with an IC
&!
of 0.73 lM. The geometry of the methyl terminus of LTA
%
does
not influence the metabolism by human platelet LTC
%
synthase.
The double bond at C-14,15 is essential for the catalytic activity
of LTA
%
hydrolase but not for binding to this enzyme.
ACD (41 mM citric acid}100 mM sodium citrate}136 mM glu-
cose) and carefully mixed. After centrifugation for 20 min at
room temperature (RT) and 200 g, platelet-rich plasma was
removed, re-acidified with 1 vol. of ACD and centrifuged for
15 min at RT and 1000 g. Pelleted platelets were resuspended
with 5 ml of washing buffer (36 mM citric acid}5 mM glucose}
5 mM KCl}2 mM CaCl
#
}1 mM MgCl
#
}103 mM NaCl, pH 6.5)
containing 0.4% (w}v) BSA and prostaglandin E
"
(final con-
centration 100 nM), according to Patscheke [13]. Platelets
were further centrifuged for 15 min at RT and 400 g, and
finally resuspended in PBS without Ca#+ and Mg#+ (PBS=).
To sediment erythrocytes, the residual blood was diluted with
1 vol. of saline [0.9% (w}v) NaCl] and 0±5 vol. of dextran T-500
[6% (w}v) in saline]. The upper layer was centrifuged for 20 min
at RT and 200 g, and the pellet subjected to erythrocyte lysis by
gentle resuspension in 1 vol. of NaCl solution (0.2%, w}v),
followed by dilution with 1 vol. of a balancing solution [1.6%
(w}v) NaCl}0.2% (w}v) sucrose].
PMNL were separated by centrifugation on Ficoll cushions
(d¯ 1.077) for 30 min at RT and 400 g. PMNL were then washed
twice with PBS= and resuspended in PBS= at a concentration of
approx. 10( cell}ml.
Purified neutrophils and eosinophil-enriched cell preparations
were obtained according to Koenderman et al. [14]. Briefly,
PMNLwere exposed toN-formylmethionyl-leucyl-phenylalanine
(10−) M) for 10 min at 37 °C in PBS= , in order to decrease the
density of neutrophils, and then centrifuged over a discontinuous
gradient of 1.082 and 1.100 g}ml Percoll. Neutrophils were
recovered at the upper interface while the lower interface collected
an enriched eosinophil preparation (10–25% eosinophils, as
assessed on cytocentrifugates stained with Giemsa). Platelets
and PMNL were counted in a Burker chamber. The viability
of PMNL was assessed by Trypan Blue dye exclusion, and was
" 90% throughout the experiments.
Erythrocytes from dextran sedimentation were diluted with
sterile, 0.9% (w}v) NaCl and centrifuged twice at RT and 200 g,
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discarding the supernatant. Red blood cells were lysed, adding
an equal volume of distilled water for 20 s, and centrifuged at
4 °C and 100000 g. The supernatant was removed, filtered
through a 0.45-lm Millipore filter and tested for LTA
%
hydrolase
activity [15].
LTA
%
and 14,15-dehydro-LTA
%
free acids were obtained
through base-catalysed hydrolysis of corresponding methyl
esters. Briefly, LTA
%
and 14,15-dehydro-LTA
%
methyl esters
were dried under a stream of nitrogen and reconstituted in ice-
cold acetone}0.25 M NaOH (4:1, v}v) ; hydrolysis was per-
formed at room temperature for 60 min and the free acids
obtained were added to human platelets (10) cells), to PMNL
(10( cells) or to red-blood-cell lysates (5 mg of protein) at a final
concentration of 0.1–10 lM. The purity of methyl esters was
checked by normal-phase HPLC, using cyclohexane}ethyl
acetate}triethylamine (99:0.5 :1, by vol.) to isocratically elute a
Lichrospher Si-100 column (4 mm¬250 mm, 5 lm; Merck) at a
flow rate of 1 ml}min. Free acids were analysed for purity by
reversed-phase HPLC (RP-HPLC) using acetonitrile}0.01 M
borate buffer, pH 10 (4:6, v}v) to isocratically elute an Ultra-
sphere RP-18 column (4 mm¬250 mm, 5 lm; Beckman Ana-
lytical, Palo Alto, CA, U.S.A.) at a flow rate of 1 ml}min [16].
UV absorbance was monitored at 280 nm and full UV spectra
(240–340 nm) acquired at a scan rate of 0.5 Hz, using a diode-
array UV detector (model 168, Beckman Analytical). The identi-
ties of methyl esters and free acids were assigned based on
retention time and on-line UV absorbance spectra.
MK-886 (1–30 lM, DMSO solution) or RP 64966 [20 lM
ethanol}1 M HCl (2:1, v}v)] was added to cell or cell-lysate
preparations 5 min before the LTA
%
or 14,15-dehydro-LTA
%
.
For studies on the irreversible inactivation of LTA
%
hydrolase,
human PMNL were preincubated for 5 min at 37 °C with 14,15-
dehydro-LTA
%
(0.1–10 lM) or with solvent alone, centrifuged
twice at RT and 200 g, resuspended in 1 ml of PBS, and finally
added with LTA
%
(1 lM).
Incubations were terminated after 1 min by addition of 2 vol.
of ice-cold methanol containing the HPLC internal standard
prostaglandin B
#
(LTA
%
experiments) or prostaglandin B
"
(14,15-
dehydro-LTA
%
experiments).
For glutathione S-transferase activity evaluation, washed
human platelets were resuspended in lysis buffer [0.05 M phos-
phate buffer (pH 7.4)}0.1 M NaCl}2 mM EDTA}aprotinin (0.1
units}ml)}pepstatin (1 lg}ml)}leupeptin (1 lg}ml)] at a concen-
tration of (3–5)¬10* ml−", and sonicated for 4¬15 s on ice, using
a sonifier (power setting 5; model XL; Heat Systems, Farming-
dale, NY, U.S.A.), equipped with a microtip. Disrupted platelets
were centrifuged for 20 min at 4 °C and 12000 g and supernatant,
representing cytosol and microsomal membranes, was tested for
enzymic activity.
Proteins were quantified spectrophotometrically using Coo-
massie Protein Assay Reagent (Pierce, Rockford, IL, U.S.A.),
with BSA as standard.
Glutathione S-transferase (EC 2.5.1.18) in platelet lysates
(100 lg of protein) was assayed spectrophotometrically at 340 nm
in a reaction system containing 1 mM glutathione, 1 mM 1-
chloro-2,4-dinitrobenzene (Sigma), 5% (v}v) ethanol and 0.1 M
sodium phosphate, pH 6.5, at 25 °C [17]. The increase in ab-
sorbance at 340 nm was monitored for 3 min using a Jasco
spectrophotometer (V-530, Tokyo, Japan), in the presence or
absence of MK-886 (30 lM). Results were expressed as nmol
of 1-chloro-2,4-dinitrobenzene–glutathione conjugate formed}
min per mg of protein, using an absorption coefficient of
9600 mol[l−"[cm−" at 340 nm.
LTA
%
-derived metabolites were analysed by RP-HPLC
coupled to diode-array UV detection, as described previously
[18]. IC
&!
was evaluated by non-linear regression using the
computer program Allfit QB [19].
Eicosanoids were purchased from Cayman Chemical Co. (Ann
Arbor, MI, U.S.A.). 14,15-Dehydro-LTA
%
methyl ester was
synthesized as described previously [20]. HPLC-grade solvents
were obtained from Merck. Type I ‘plus ’ water was obtained
using a MilliQ Plus water purifier (Millipore, Molsheim, France),
fed with double-distilled water.
RESULTS
In agreement with a preliminary report [20], RP-HPLC analysis
of incubates of human platelets exposed to 14,15-dehydro-
LTA
%
(1 lM) revealed a chromatographic profile similar to that
observed using authentic LTA
%
, except all the chromatographic
peaks moved to shorter retention times. The peak corresponding
to 14,15-dehydro-LTC
%
showed a unique UV absorption spec-
trum, with k
max
at 279 nm and shoulders at 269 and 290 nm,
and was structurally characterized by controlled metabolism and
electrospray tandem mass spectrometry, collision induced dis-
sociation [20].
In order to rule out the possibility that the conversion of 14,15-
dehydro-LTA
%
into 14,15-dehydro-LTC
%
was the result of gluta-
thione S-transferase activity, rather than the unique LTC
%
syn-
thase, we tested the effect of compound MK-886, which we
recently reported was an inhibitor of the human platelet LTC
%
synthase [21]. MK-886 dose-dependently inhibited the formation
of 14,15-dehydro-LTC
%
with an IC
&!
of 4.7 lM (Table 1), which
is similar to that observed using authentic LTA
%
as substrate. A
glutathione S-transferase activity of 26.6³9.0 nmol}min per mg
of protein (mean³S.E.M., n¯ 3) was evaluated in lysed human
platelets, and was only slightly affected (22³9% inhibition) by
the presence of MK-886 at a concentration (30 lM) resulting in
complete inhibition of 14,15-dehydro-LTC
%
formation in intact
platelets.
The affinity of 14,15-dehydro-LTA
%
for LTC
%
synthase was
very similar to that observed with authentic LTA
%
(Figure 1) :
apparent K
m
and V
max
of 1.6 lM and 200 pmol}min per 10)
platelets were measured, to be compared with 2 lM and
200 pmol}min per 10) platelets respectively for LTA
%
. Addition
of LTA
%
to lysed erythrocytes resulted in the formation of LTB
%
;
this was completely prevented by preincubation with 20 lM RP
64966, a specific inhibitor of LTA
%
hydrolase [22]. No difference
was observed between the chromatographic profiles obtained in
the presence or in the absence of the inhibitor when 14,15-
dehydro-LTA
%
was used, indicating lack of metabolism by the
red-blood-cell LTA
%
hydrolase (Figure 2).
Table 1 Effect of MK-886 on LTC4 synthase metabolism of 14,15-dehydro-
LTA4 in intact human platelets
Washed human platelets (108 cells) were incubated for 1 min with 14,15-dehydro-LTA4 (1 lM)
in the absence or the presence of MK-886 (1–30 lM). Samples were analysed by RP-HPLC.
Control incubations showed production of 75³9 pmol of 14,15-dehydro-LTC4. Results are
expressed as the percentage of control, as means³S.E.M. (n ¯ 3).
MK-886 (lM)
Production of
14,15-dehydro-LTC4
(%)
1 92.3³1.9
3 81.4³3
10 23.1³2.4
30 7.3³3
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Figure 1 Substrate-dependent transformation of LTA4 and 14,15-dehydro-
LTA4 by washed human platelets
Washed human platelets (108 cells) were incubated for 1 min with 14,15-dehydro (DH)-LTA4 or
LTA4 (0.1–10 lM). Samples were analysed by RP-HPLC. Data are means³S.E.M. (n ¯ 3).
The inset shows Lineweaver–Burk transformations of the data.
Figure 2 RP-HPLC separation of LTA4 and 14,15-dehydro-LTA4 metabolites
after incubation with red blood cell lysates
Red-blood-cell lysates (5 mg of protein) were incubated for 1 min with (A) 1 lM LTA4 and (B)
1 lM 14,15-dehydro-LTA4. LTB4 was identified by on-line UV-spectrum analysis and retention
times of synthetic standards. The chromatographic profile obtained with 14,15-dehydro-LTA4
was not modified by the presence of 20 lM RP-64966, a specific LTA4 hydrolase inhibitor, and
was identical with that obtained in the absence of red-blood-cell lysate. Significant peaks eluting
before and after the internal standard, prostaglandin B1 (PGB1), represent the products of non-
enzymic hydrolysis of 14,15-dehydro-LTA4. A.U., absorbance units.
Addition of authentic LTA
%
to human PMNL resulted in the
formation of significant amounts of LTB
%
and of its x-oxidized
metabolites, namely 20-hydroxy- and 20-carboxy-LTB
%
(Figure
Figure 3 RP-HPLC separation of LTA4 and 14,15-dehydro-LTA4 metabolites
after incubation with human PMNL
Human PMNL (107 cells) were incubated for 10 min with (A) 10 lM LTA4 and (B) 10 lM
14,15-dehydro-LTA4. Incubation was terminated by addition of 2 vol. of ice-cold methanol.
Sample was extracted on a solid-phase cartridge (Supelclean C18) and analysed by RP-HPLC.
LTA4 metabolites [LTB4, 20-hydroxy-LTB4 (20-OH-LTB4), 20-carboxy-LTB4(20-COOH-LTB4)]
were identified by on-line UV-spectrum analysis and retention times of synthetic standards.
14,15-Dehydro-LTC4 was identified by on-line UV-spectrum analysis and retention times of
mass spectrometry-characterized platelet metabolites. A.U., absorbance units.
3A), in agreement with previously published data [18,23]. No
significant metabolism was observed on addition of up to 10 lM
14,15-dehydro-LTA
%
, except for minor amounts of 14,15-
dehydro-LTC
%
(Figure 3B). In order to test if eosinophil
contamination could account for the 14,15-dehydro-LTC
%
pro-
duction by PMNL, highly purified neutrophils and eosinophil-
enriched preparations were checked. The results obtained showed
that neutrophils were not able to enzymically process 14,15-
dehydro-LTA
%
to any extent, whereas significant amounts of
14,15-dehydro-LTC
%
were synthesized by eosinophil-enriched
preparations (Figure 4).
Preincubation of neutrophils with 14,15-dehydro-LTA
%
(0.1–10 lM) caused irreversible inactivation of LTA
%
hydrolase,
with an IC
&!
of 0.73 lM (Table 2).
DISCUSSION
The results obtained using a unique LTA
%
analogue show that
substitution of a double with a triple bond at C-14,15 leaves a
substrate suitable for metabolism by LTC
%
synthase. The re-
sulting14,15-dehydro-LTC
%
analoguehasbeenpreviouslycharac-
terized by RP-HPLC with on-line UV spectroscopy, enzymic
conversion and mass spectrometry.
LTC
%
synthase, as shown by recent cloning and expression
[5,6,24], does not belong to the family of glutathione S-trans-
ferases, but presents significant similarity to another protein
involved in leukotriene metabolism, namely the ‘five lipoxygenase
activating protein’. Further supporting this observation, a known
5-lipoxygenase-activating-protein inhibitor, compound MK-886,
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Figure 4 RP-HPLC separation of 14,15-dehydro-LTA4 metabolites after
incubation with purified human neutrophils and enriched eosinophil pre-
parations
(A) Purified human neutrophils (107 cells) and (B) enriched eosinophils (5¬106 cells) were
incubated for 10 min with 10 lM 14,15-dehydro-LTA4 (14,15-DH-LTA4). Incubation was
terminated by addition of 2 vol. of ice-cold methanol and, after centrifugation, an aliquot of the
sample was directly analysed by RP-HPLC. A.U., absorbance units.
Table 2 Effect of preincubation with 14,15-dehydro-LTA4 on metabolism of
synthetic LTA4 by human PMNL
Human PMNL (107 cells) were incubated for 10 min in the absence or the presence of 14,15-
dehydro-LTA4 (0.1–10 lM). Cells were washed twice with PBS and incubated with LTA4
(1 lM) for 10 min. After addition of 2 vol. ice-cold methanol and centrifugation, an aliquot of
the sample was directly analysed by RP-HPLC. Control incubations showed production of
308³16 pmol of LTA4 hydrolase-derived metabolites, namely LTB4, 20-hydroxy-LTB4 and 20-
carboxy-LTB4 (LTB4s). Results are expressed as the percentage of control³S.E.M. (n ¯ 3).
14,15-Dehydro-LTA4
(lM)
Production of
LTB4s (%)
0.1 96.0³13.5
0.3 72.2³11.8
1 38.7³6.3
3 27.6³8.4
10 3.7³1.5
was reported to dose-dependently inhibit cloned, expressed LTC
%
synthase. In agreement with these data, we showed recently that
MK-886, as well as a different, structurally unrelated 5-lipoxy-
genase-activating-protein inhibitor, was able to modulate human
platelet LTC
%
synthase [21].
Inhibition of 14,15-dehydro-LTA
%
metabolism by human
platelets on preincubation with compound MK-886, provides
pharmacological identification of LTC
%
synthase as the enzymic
activity responsible for the synthesis of the observed 14,15-
dehydro-LTC
%
analogue.
A previous report had shown that saturation of the 14,15
double bond of LTA
%
did not affect metabolism by purified
guinea-pig LTC
%
synthase [9] ; in contrast, later evidence pointed
to significant differences in substrate specificity between human
platelet and guinea-pig LTC
%
synthase. Using the guinea-pig
enzyme, LTA
%
methyl ester showed a V
max
that was 4-fold higher
than that for LTA
%
, whereas the same substrate presented a V
max
that was 14-fold lower than for LTA
%
using human platelet LTC
%
synthase [10]. Another LTA
%
analogue, 14,15-LTA
%
, was found
not to be processed by the human platelet LTC
%
synthase, but
still provided a good substrate for the guinea-pig enzyme, with a
V
max
of twice that for LTA
%
. In the present paper we provide
evidence that 14,15-dehydro-LTA
%
represents a substrate that is
indistinguishable from authentic LTA
%
by human LTC
%
synthase.
Therefore modifications of the lipophilic chain of LTA
%
do not
affect either binding or catalytic conversion by LTC
%
synthase,
thus providing additional information on the structural require-
ments for interactions with this biologically relevant enzyme.
14,15-Dehydro-LTA
%
was not enzymically converted by hu-
man PMNL or red-blood-cell LTA
%
hydrolase. Furthermore,
preincubationwith 14,15-dehydro-LTA
%
before addition ofLTA
%
resulted in potent, irreversible inhibition of LTA
%
hydrolase
activity. These data support results obtained with leukotriene A
$
and rat neutrophils, showing that the double bond at C-14,15
represents a critical feature for the enzymic conversion carried
out by the specific LTA
%
hydrolase. Interaction with the binding
site of the enzyme does not appear to be affected by the
modification of the D"% double bond. In fact leukotriene A
$
and
14,15-dehydro-LTA
%
, as well as authentic LTA
%
, irreversibly
bind to human LTA
%
hydrolase preventing further enzymic
activity. On LTA
%
, the cis geometry of the double bond at C-
14,15 might impose a specific orientation of the lipophilic chain,
resulting in correct interaction of the conjugated system with the
enzyme.
Reviewing data obtained with different LTA
%
analogues shows
that the overall structure of the lipophilic chain seems to be less
important than the presence of the 14,15 double bond in
connection with the possibility of metabolism by the LTA
%
hydrolase: leukotriene A
&
, possessing an additional double bond
at C-17,18 is still efficiently metabolized to leukotriene B
&
,
although the apparent V
max
is severalfold lower than that for
authentic LTA
%
[12]. Interestingly, leukotriene A
&
is also a
suitable substrate for LTC
%
synthase, but enzymic conversion
appears to be 20-fold less efficient than with the specific substrate
LTA
%
.
In conclusion, we found that the substitution with a triple
bond of the double bond at C-14,15 of LTA
%
does not affect the
metabolism by human platelet LTC
%
synthase, but completely
prevents metabolism by erythrocyte and PMNL LTA
%
hydrolase.
These data provide additional information on the structural
requirements for binding and metabolism by these two important
enzymes. Furthermore, the observation of a preserved biological
activity by 14,15-dehydro-LTC
%
[20] suggests that 14,15-de-
hydro-LTA
%
may represent a valuable tool for the study of the
pathophysiological role of transcellular synthesis of cysteinyl
leukotrienes in complex organ systems [25].
Compound RP 64966 was kindly given by Dr. N. Dereu (Rhone-Poulenc Rorer,
Departement de Chimie Pharmaceutique et de Biologie, 94403 Vitry sur Seine,
France) ; compound MK-886 was kindly given by Dr. A. Ford-Hutchinson (Merck-
Frosst, Pointe-Claire Dorval, Quebec, Canada).
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